Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Dec;116(7):2971–2982. doi: 10.1111/j.1476-5381.1995.tb15952.x

Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226.

J M Lundberg 1, A Modin 1
PMCID: PMC1909221  PMID: 8680732

Abstract

1. Recently, a potent non-peptide antagonist of neuropeptide Y (NPY)-Y1 receptors has been developed. In this study, the selectivity of this compound, BIBP 3226, as a functional Y1 receptor antagonist, and the possible role of endogenous NPY in sympathetic vasoconstriction in different vascular beds have been investigated in anaesthetized pigs. 2. BIBP 3226 specifically displaced [125I]-NPY binding with an IC50 value of 7 nM in membranes of pig renal arteries, which also were responsive to a Y1 receptor agonist, but had only minor effects in the pig spleen (IC50 55 microM), where instead [125I]-NPY binding was markedly inhibited by a Y2 receptor agonist. IC50 values in the same nM range for BIBP 3226 were also observed in rat and bovine cortex and dog spleen. 3. In anaesthetized control pigs in vivo BIBP 3226 (1 and 3 mg kg-1) markedly inhibited the vasoconstrictor effects of the Y1 receptor agonist [Leu31, Pro34] NPY(1-36), without influencing the responses to the Y2 receptor agonist N-acetyl [Leu28, Leu31] NPY(24-36), or to noradrenaline, phenylephrine, alpha,beta-methylene adenosine triphosphate or angiotensin II. 4. High frequency stimulation of the sympathetic trunk in control pigs caused a biphasic vasoconstrictor response in nasal mucosa, hind limb and skin: there was an immediate, peak response, followed by a long-lasting vasoconstriction. BIBP 3226 (1 and 3 mg kg-1) reduced the second phase by about 50% but had no effect on the peak response. In the spleen, kidney and mesenteric circulation (which lack the protracted response) BIBP 3226 was likewise without effect on the maximal vasoconstriction, and did not influence noradrenaline overflow from spleen and kidney. 5. The corresponding S-enantiomer BIBP 3435 had only marginal influence on [125I]-NPY binding (microM range) and did not inhibit the vasoconstrictor effects of any of the agonists used, including the Y1 receptor peptide agonist. Furthermore, BIBP 3435 did not affect the response to sympathetic nerve stimulation. Both BIBP 3435 and BIBP 3226 caused a slight transient decrease in mean arterial blood pressure (by about 5 and 15 mmHg at 1 mg kg-1 and 3 mg kg-1, respectively), accompanied by splenic and mesenteric vasodilatation, suggesting that this effect was unrelated to Y1 receptor blockade. 6. The peptide YY (PYY)- and NPY-evoked vasoconstriction in the kidney of reserpine-treated pigs was markedly reduced (by 95%) by BIBP 3226 while the vasoconstrictor effect in the spleen was attenuated by only 20%. BIBP 3226 did not influence stimulation-evoked NPY release. The vasoconstrictor response in reserpine-treated pigs to single impulse stimulation, which is observed only in nasal mucosa and hind limb, was unchanged regarding maximal amplitude and the integrated effect was only moderately reduced (by about 25%) in the presence of BIBP 3226 (1 mg kg-1). BIBP 3226 (1 mg kg-1) markedly reduced (by 55-70%) the long-lasting vascular response (total integrated blood flow reduction) evoked by sympathetic nerve stimulation at high frequency (40 impulses at 20 Hz) in spleen, kidney, nasal mucosa and hind limb. Furthermore, the maximal amplitude of the vasoconstriction was reduced mainly in the kidney (by 60%) and also in the spleen (by 40%). 7. It is concluded that BIBP 3226 can act as a selective Y1 receptor antagonist in the pig. Endogenous NPY via Y1 receptor activation may play a role in evoking the long-lasting vasoconstriction seen in nasal mucosa, hind limb and skin after high frequency stimulation of sympathetic nerves in control pigs. Furthermore, NPY via Y1 receptor mechanisms seems to be of major importance for the long-lasting component of the reserpine resistant sympathetic vasoconstriction in many vascular beds, and for the maximal vasoconstrictor response in the kidney. Circulating NPY and PYY induce splenic vasoconstriction via Y2-receptors in contrast to neuronally released NPY which mainly activates Y1 receptors.

Full text

PDF
2975

Images in this article

2975Figure 3
on p.2975
2976Figure 4
on p.2976
2976Figure 5
on p.2976
2977Figure 7
on p.2977
2978Figure 8
on p.2978
2979Figure 10
on p.2979

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bao J. X. Sympathetic neuromuscular transmission in rat tail artery: a study based on electrochemical, electrophysiological and mechanical recording. Acta Physiol Scand Suppl. 1993;610:1–58. [PubMed] [Google Scholar]
  2. Bulloch J. M., McGrath J. C. Blockade of vasopressor and vas deferens responses by alpha,beta-methylene ATP in the pithed rat. Br J Pharmacol. 1988 May;94(1):103–108. doi: 10.1111/j.1476-5381.1988.tb11504.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burnstock G. Sympathetic purinergic transmission in small blood vessels. Trends Pharmacol Sci. 1988 Apr;9(4):116–117. doi: 10.1016/0165-6147(88)90185-x. [DOI] [PubMed] [Google Scholar]
  4. Doods H. N., Krause J. Different neuropeptide Y receptor subtypes in rat and rabbit vas deferens. Eur J Pharmacol. 1991 Oct 29;204(1):101–103. doi: 10.1016/0014-2999(91)90841-d. [DOI] [PubMed] [Google Scholar]
  5. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Håkanson R., Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept. 1984 Apr;8(3):225–235. doi: 10.1016/0167-0115(84)90064-8. [DOI] [PubMed] [Google Scholar]
  6. Eva C., Keinänen K., Monyer H., Seeburg P., Sprengel R. Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family. FEBS Lett. 1990 Oct 1;271(1-2):81–84. doi: 10.1016/0014-5793(90)80377-u. [DOI] [PubMed] [Google Scholar]
  7. Fuhlendorff J., Gether U., Aakerlund L., Langeland-Johansen N., Thøgersen H., Melberg S. G., Olsen U. B., Thastrup O., Schwartz T. W. [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc Natl Acad Sci U S A. 1990 Jan;87(1):182–186. doi: 10.1073/pnas.87.1.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Grundemar L., Jonas S. E., Mörner N., Högestätt E. D., Wahlestedt C., Håkanson R. Characterization of vascular neuropeptide Y receptors. Br J Pharmacol. 1992 Jan;105(1):45–50. doi: 10.1111/j.1476-5381.1992.tb14208.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Herzog H., Hort Y. J., Ball H. J., Hayes G., Shine J., Selbie L. A. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5794–5798. doi: 10.1073/pnas.89.13.5794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lacroix J. S., Stjärne P., Anggärd A., Lundberg J. M. Sympathetic vascular control of the pig nasal mucosa (III): Co-release of noradrenaline and neuropeptide Y. Acta Physiol Scand. 1989 Jan;135(1):17–28. doi: 10.1111/j.1748-1716.1989.tb08546.x. [DOI] [PubMed] [Google Scholar]
  11. Lacroix J. S., Stjärne P., Anggård A., Lundberg J. M. Sympathetic vascular control of the pig nasal mucosa (2): Reserpine-resistant, non-adrenergic nervous responses in relation to neuropeptide Y and ATP. Acta Physiol Scand. 1988 Jun;133(2):183–197. doi: 10.1111/j.1748-1716.1988.tb08398.x. [DOI] [PubMed] [Google Scholar]
  12. Larhammar D., Blomqvist A. G., Yee F., Jazin E., Yoo H., Wahlested C. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem. 1992 Jun 5;267(16):10935–10938. [PubMed] [Google Scholar]
  13. Lundberg J. M., Franco-Cereceda A., Hemsén A., Lacroix J. S., Pernow J. Pharmacology of noradrenaline and neuropeptide tyrosine (NPY)-mediated sympathetic cotransmission. Fundam Clin Pharmacol. 1990;4(4):373–391. doi: 10.1111/j.1472-8206.1990.tb00692.x. [DOI] [PubMed] [Google Scholar]
  14. Lundberg J. M., Fried G., Pernow J., Theodorsson-Norheim E., Anggård A. NPY--a mediator of reserpine-resistant, non-adrenergic vasoconstriction in cat spleen after preganglionic denervation? Acta Physiol Scand. 1986 Jan;126(1):151–152. doi: 10.1111/j.1748-1716.1986.tb07799.x. [DOI] [PubMed] [Google Scholar]
  15. Lundberg J. M., Hemsén A., Larsson O., Rudehill A., Saria A., Fredholm B. B. Neuropeptide Y receptor in pig spleen: binding characteristics, reduction of cyclic AMP formation and calcium antagonist inhibition of vasoconstriction. Eur J Pharmacol. 1988 Jan 5;145(1):21–29. doi: 10.1016/0014-2999(88)90344-5. [DOI] [PubMed] [Google Scholar]
  16. Lundberg J. M., Martinsson A., Hemsén A., Theodorsson-Norheim E., Svedenhag J., Ekblom B., Hjemdahl P. Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Commun. 1985 Nov 27;133(1):30–36. doi: 10.1016/0006-291x(85)91837-6. [DOI] [PubMed] [Google Scholar]
  17. Lundberg J. M., Rudehill A., Sollevi A., Fried G., Wallin G. Co-release of neuropeptide Y and noradrenaline from pig spleen in vivo: importance of subcellular storage, nerve impulse frequency and pattern, feedback regulation and resupply by axonal transport. Neuroscience. 1989;28(2):475–486. doi: 10.1016/0306-4522(89)90193-0. [DOI] [PubMed] [Google Scholar]
  18. Lundberg J. M., Rudehill A., Sollevi A., Hamberger B. Evidence for co-transmitter role of neuropeptide Y in the pig spleen. Br J Pharmacol. 1989 Mar;96(3):675–687. doi: 10.1111/j.1476-5381.1989.tb11868.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lundberg J. M., Stjarne L. Neuropeptide Y (NPY) depresses the secretion of 3H-noradrenaline and the contractile response evoked by field stimulation, in rat vas deferens. Acta Physiol Scand. 1984 Mar;120(3):477–479. doi: 10.1111/j.1748-1716.1984.tb07410.x. [DOI] [PubMed] [Google Scholar]
  20. Lundberg J. M., Tatemoto K. Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol Scand. 1982 Dec;116(4):393–402. doi: 10.1111/j.1748-1716.1982.tb07157.x. [DOI] [PubMed] [Google Scholar]
  21. Lundberg J. M., Terenius L., Hökfelt T., Martling C. R., Tatemoto K., Mutt V., Polak J., Bloom S., Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand. 1982 Dec;116(4):477–480. doi: 10.1111/j.1748-1716.1982.tb07171.x. [DOI] [PubMed] [Google Scholar]
  22. Modin A. Non-adrenergic, non-cholinergic vascular control with reference to neuropeptide Y, vasoactive intestinal polypeptide and nitric oxide. Acta Physiol Scand Suppl. 1994;622:1–74. [PubMed] [Google Scholar]
  23. Modin A., Pernow J., Lundberg J. M. Evidence for two neuropeptide Y receptors mediating vasoconstriction. Eur J Pharmacol. 1991 Oct 15;203(2):165–171. doi: 10.1016/0014-2999(91)90711-x. [DOI] [PubMed] [Google Scholar]
  24. Modin A., Pernow J., Lundberg J. M. Neuropeptide Y and differential sympathetic control of splenic blood flow and capacitance function in the pig and dog. Acta Physiol Scand. 1993 Jan;147(1):15–25. doi: 10.1111/j.1748-1716.1993.tb09468.x. [DOI] [PubMed] [Google Scholar]
  25. Modin A., Pernow J., Lundberg J. M. Repeated renal and splenic sympathetic nerve stimulation in anaesthetized pigs: maintained overflow of neuropeptide Y in controls but not after reserpine. J Auton Nerv Syst. 1994 Oct;49(2):123–134. doi: 10.1016/0165-1838(94)90132-5. [DOI] [PubMed] [Google Scholar]
  26. Modin A., Pernow J., Lundberg J. M. Sympathetic regulation of skeletal muscle blood flow in the pig: a non-adrenergic component likely to be mediated by neuropeptide Y. Acta Physiol Scand. 1993 May;148(1):1–11. doi: 10.1111/j.1748-1716.1993.tb09525.x. [DOI] [PubMed] [Google Scholar]
  27. Morris J. L. Roles of neuropeptide Y and noradrenaline in sympathetic neurotransmission to the thoracic vena cava and aorta of guinea-pigs. Regul Pept. 1991 Feb 26;32(3):297–310. doi: 10.1016/0167-0115(91)90023-a. [DOI] [PubMed] [Google Scholar]
  28. Morris J. L., Sabesan S. Comparison of the NPY receptors mediating vasoconstriction of the guinea-pig uterine artery and thoracic vena cava using a range of NPY analogues. Neuropeptides. 1994 Jan;26(1):21–28. doi: 10.1016/0143-4179(94)90088-4. [DOI] [PubMed] [Google Scholar]
  29. Muramatsu I. The effect of reserpine on sympathetic, purinergic neurotransmission in the isolated mesenteric artery of the dog: a pharmacological study. Br J Pharmacol. 1987 Jul;91(3):467–474. doi: 10.1111/j.1476-5381.1987.tb11238.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ohlén A., Persson M. G., Lindbom L., Gustafsson L. E., Hedqvist P. Nerve-induced nonadrenergic vasoconstriction and vasodilatation in skeletal muscle. Am J Physiol. 1990 May;258(5 Pt 2):H1334–H1338. doi: 10.1152/ajpheart.1990.258.5.H1334. [DOI] [PubMed] [Google Scholar]
  31. Pernow J., Kahan T., Lundberg J. M. Neuropeptide Y and reserpine-resistant vasoconstriction evoked by sympathetic nerve stimulation in the dog skeletal muscle. Br J Pharmacol. 1988 Jul;94(3):952–960. doi: 10.1111/j.1476-5381.1988.tb11609.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Pernow J., Lundberg J. M. Modulation of noradrenaline and neuropeptide Y (NPY) release in the pig kidney in vivo: involvement of alpha 2, NPY and angiotensin II receptors. Naunyn Schmiedebergs Arch Pharmacol. 1989 Oct;340(4):379–385. doi: 10.1007/BF00167038. [DOI] [PubMed] [Google Scholar]
  33. Pernow J., Lundberg J. M. Release and vasoconstrictor effects of neuropeptide Y in relation to non-adrenergic sympathetic control of renal blood flow in the pig. Acta Physiol Scand. 1989 Aug;136(4):507–517. doi: 10.1111/j.1748-1716.1989.tb08696.x. [DOI] [PubMed] [Google Scholar]
  34. Pernow J., Thorén P., Millberg B. I., Lundberg J. M. Renal sympathetic nerve activation in relation to reserpine-induced depletion of neuropeptide Y in the kidney of the rat. Acta Physiol Scand. 1988 Sep;134(1):53–59. doi: 10.1111/j.1748-1716.1988.tb08458.x. [DOI] [PubMed] [Google Scholar]
  35. Potter E. K., Barden J. A., McCloskey M. J., Selbie L. A., Tseng A., Herzog H., Shine J. A novel neuropeptide Y analog, N-acetyl [Leu28,Leu31]neuropeptide Y-(24-36), with functional specificity for the presynaptic (Y2) receptor. Eur J Pharmacol. 1994 May 17;267(3):253–262. doi: 10.1016/0922-4106(94)90148-1. [DOI] [PubMed] [Google Scholar]
  36. Ramme D., Regenold J. T., Starke K., Busse R., Illes P. Identification of the neuroeffector transmitter in jejunal branches of the rabbit mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol. 1987 Sep;336(3):267–273. doi: 10.1007/BF00172677. [DOI] [PubMed] [Google Scholar]
  37. Rudehill A., Olcén M., Sollevi A., Hamberger B., Lundberg J. M. Release of neuropeptide Y upon haemorrhagic hypovolaemia in relation to vasoconstrictor effects in the pig. Acta Physiol Scand. 1987 Dec;131(4):517–523. doi: 10.1111/j.1748-1716.1987.tb08271.x. [DOI] [PubMed] [Google Scholar]
  38. Rudolf K., Eberlein W., Engel W., Wieland H. A., Willim K. D., Entzeroth M., Wienen W., Beck-Sickinger A. G., Doods H. N. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur J Pharmacol. 1994 Dec 27;271(2-3):R11–R13. doi: 10.1016/0014-2999(94)90822-2. [DOI] [PubMed] [Google Scholar]
  39. Ruffolo R. R., Jr, Nichols A. J., Stadel J. M., Hieble J. P. Structure and function of alpha-adrenoceptors. Pharmacol Rev. 1991 Dec;43(4):475–505. [PubMed] [Google Scholar]
  40. Sheikh S. P., Håkanson R., Schwartz T. W. Y1 and Y2 receptors for neuropeptide Y. FEBS Lett. 1989 Mar 13;245(1-2):209–214. doi: 10.1016/0014-5793(89)80223-6. [DOI] [PubMed] [Google Scholar]
  41. Stark R. D. Conductance or resistance? Nature. 1968 Feb 24;217(5130):779–779. doi: 10.1038/217779a0. [DOI] [PubMed] [Google Scholar]
  42. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci U S A. 1982 Sep;79(18):5485–5489. doi: 10.1073/pnas.79.18.5485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Theodorsson-Norheim E., Hemsén A., Lundberg J. M. Radioimmunoassay for neuropeptide Y (NPY): chromatographic characterization of immunoreactivity in plasma and tissue extracts. Scand J Clin Lab Invest. 1985 Jun;45(4):355–365. doi: 10.3109/00365518509161019. [DOI] [PubMed] [Google Scholar]
  44. Wahlestedt C., Yanaihara N., Håkanson R. Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept. 1986 Feb;13(3-4):307–318. doi: 10.1016/0167-0115(86)90048-0. [DOI] [PubMed] [Google Scholar]
  45. von Kügelgen I., Starke K. Noradrenaline and adenosine triphosphate as co-transmitters of neurogenic vasoconstriction in rabbit mesenteric artery. J Physiol. 1985 Oct;367:435–455. doi: 10.1113/jphysiol.1985.sp015834. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES